CMXC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMXC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Cell MedX's Capital Expenditure for the three months ended in Feb. 2024 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Feb. 2024 was $-0.04 Mil.
GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.
The historical data trend for Cell MedX's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cell MedX Annual Data | |||||||||||||||||||||
Trend | May14 | May15 | May16 | May17 | May18 | May19 | May20 | May21 | May22 | May23 | |||||||||||
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Cell MedX Quarterly Data | ||||||||||||||||||||
May19 | Aug19 | Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | |
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Medical Devices subindustry, Cell MedX's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Cell MedX's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Cell MedX's Capex-to-Operating-Cash-Flow falls into.
Cell MedX's Capex-to-Operating-Cash-Flow for the fiscal year that ended in May. 2023 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (0) | / | -0.272 | |
= | N/A |
Cell MedX's Capex-to-Operating-Cash-Flow for the quarter that ended in Feb. 2024 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (0) | / | -0.038 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cell MedX (OTCPK:CMXC) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Thank you for viewing the detailed overview of Cell MedX's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Jeffs | 10 percent owner | FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL |
Dwayne Yaretz | director, officer: Chief Executive Officer | SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7 |
Bradley S Hargreaves | 10 percent owner | 904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1 |
Frank Mcenulty | director, officer: CEO, CFO, Treas., Sec | 4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475 |
Joao Dacosta | director, officer: COO | #810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2 |
George Adams | director | 7535 CONSERVATION ROAD, GUELPH A6 N1H6J1 |
Terrance George Owen | director, officer: CEO | 635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO |
John David Sanderson | officer: Chief Medical Officer | 9 ISLANDVIEW, IRVINE CA 92604 |
Yanika S Silina | officer: CFO, Treasurer and Secretary | 789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2 |
Jean M Arnett | 10 percent owner | 121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8 |
Ean Kremer | director, officer: Chief Technology Officer | C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103 |
From GuruFocus
By Kyle Ferguson Kyle Ferguson • 11-11-2016
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.